RE:Simply Wall Street determines ONCY fair value at $157 p/sAnd because Matt Coffey hired "new" doctoral level scientists, who have worked to bring ONCY through the breast, pancreatic, colorectal and the AWARE-1 clinical studies in partnership with Pfizer/Merck KGaA Serono and Roche ONCY is a different company than some seem to remember.
As a consequence independent stock analysis companies like SWS determine that ONCY's fair value is in excess of US$8 Billion or $157 per share.
Now major research hospitals like Memorial Sloan Kettering are seeking to affect similar immune responses that ONCY had demonstrated pelareorep activates in Sloan Kettering's attempt to follow in ONCY's footsteps in the treatment of pancreatic cancer, for example.
ONCY is "no longer your father's Oldsmobile", as some keep trying to contend.